Jiahui International Hospital (Shanghai), Shanghai, China.
Qingdao Mental Health Center, Qingdao, China.
Eur Arch Psychiatry Clin Neurosci. 2024 Sep;274(6):1327-1332. doi: 10.1007/s00406-024-01763-6. Epub 2024 Mar 27.
Several studies have reported that baseline symptom severity in patients with schizophrenia (SCZ) is associated with the efficacy of antipsychotic medication. Overweight/obesity is common in SCZ and has also been reported to be correlated with therapeutic response to antipsychotics. This study aimed to evaluate whether baseline body mass index (BMI) and disease severity were associated with improvements in negative symptoms in patients with first-episode and medication-naïve (FEMN) SCZ. A total of 241 FEMN patients were recruited in this study and treated with oral risperidone over 3 months. Clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) and BMI was assessed at baseline and 3-month follow-up. We found that baseline BMI was correlated with the baseline severity of symptoms. Baseline BMI or baseline disease severity was associated with improvement in negative symptoms after 3 months of treatment. Linear regression analysis indicated that the interaction of BMI and disease severity at baseline was associated with improvement in negative symptoms in the early stage of SCZ after controlling for sex, age, and dose of risperidone. Our study suggests that the interaction of baseline BMI and disease severity may play a role in predicting negative symptom improvement after 3 months of risperidone treatment.
多项研究报告称，精神分裂症（SCZ）患者的基线症状严重程度与抗精神病药物的疗效相关。超重/肥胖在 SCZ 中很常见，也有报道称与抗精神病药物的治疗反应相关。本研究旨在评估首发、未经药物治疗（FEMN）的 SCZ 患者的基线体重指数（BMI）和疾病严重程度是否与阴性症状的改善相关。本研究共招募了 241 名 FEMN 患者，他们接受了为期 3 个月的口服利培酮治疗。临床症状通过阳性和阴性症状量表（PANSS）进行测量，BMI 在基线和 3 个月随访时进行评估。我们发现，基线 BMI 与症状的基线严重程度相关。基线 BMI 或基线疾病严重程度与治疗 3 个月后阴性症状的改善相关。线性回归分析表明，在控制性别、年龄和利培酮剂量后，基线时 BMI 和疾病严重程度的相互作用与 SCZ 早期阴性症状的改善相关。我们的研究表明，基线 BMI 和疾病严重程度的相互作用可能在预测利培酮治疗 3 个月后阴性症状的改善方面发挥作用。
